We are testing a new treatment using patients' own dendritic cells to help manage severe bleeding in hemophilia A. This study aims to see if it can improve the body's tolerance to a crucial clotting factor.
Health conditions and diseases that the clinical trial is designed to study and treat.
Hemophilia A with anti factor VIII is a rare bleeding disorder where the body produces antibodies that inhibit the action of clotting factor VIII, leading to increased risk of bleeding and complications during injuries or surgeries.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.